Dianne Petrone, MD
Rheumatology · Dallas, TXNPI 1710919287
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $246,628 of the $400,559 with a category attached, or 61.6%. It is spread thinly across 39 manufacturers, the largest accounting for just 19.4%. Reporting peaked in 2019 at $127,589 and has fallen 79.0% since, to $26,812 in 2025. Among rheumatology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,833 payments — averaging $218.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$78K
- Amgen$61K
- Novartis$61K
- Johnson & Johnson$59K
- Janssen Scientific Affairs, LLC$47K
- Sanofi$28K
- plus $66K from 33 others
Across 23 payments — averaging $1594.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10K
- Janssen Research & Development, LLC$8K
- GSK$6K
- Gilead$5K
- AbbVie$5K
- Pfizer$4K
What the payments were for
- Consulting fees$68,31117%
- Speaking & faculty fees$246,62862%
- Travel & lodging$37,8749%
- Food & beverage$47,34012%
- Education$4060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$400,559 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 40 | $387,128 |
| Enbrel SureclickEtanercept | 29 | $256,916 |
| Orencia ClickjectAbatacept | 41 | $238,462 |
| Humira(Cf)Adalimumab | 16 | $218,705 |
| OrenciaAbatacept | 17 | $134,329 |
| EnbrelEtanercept | 14 | $100,340 |
| Cevimeline Hcl | 65 | $11,991 |
| Hydroxychloroquine Sulfate | 245 | $6,391 |
| MethotrexateMethotrexate Sodium | 148 | $3,420 |
| Diclofenac Sodium | 14 | $2,148 |
| Pilocarpine Hcl | 20 | $1,989 |
| Mycophenolate Mofetil | 11 | $792 |
| Tramadol Hcl | 71 | $552 |
| Prednisone | 96 | $520 |
| Celecoxib | 19 | $399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $77,905 | $218,70516 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $25,595 | $134,32917 claims |
| AmgenEnbrel | $61,108 | $100,34014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Dallas
- John CushDallas$3.7M
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Stanley CohenDallas$318K
- Joanna GeslaniDallas$242K
- Sharad LakhanpalDallas$229K
- Iftikhar ChowdhryDallas$226K
- Srilatha KothandaramanDallas$140K
- Leyka BarbosaDallas$108K
- Robert JenkinsDallas$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.